Bronchial AsthmaNCT06376617
Pattern Of Isolated Fungi From Bronchoalveolar Lavage Among Patients With Bronchial Asthma
A study testing fibroptic bronchoscopy in people with Bronchial Asthma, run by Mansoura University.
Trial summary
This study is to assess the pattern of isolated fungi from the respiratory air way (bronchial tree) from bronchoalvealar lavage (BAL) in asthmatic patients with uncontrolled or difficult to treat asthma Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Bronchial Asthma
- What is being tested?
- fibroptic bronchoscopy
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 60 participants
- Where
- No sites listed yet
- Study dates
- 25 Apr 2024to 20 May 2025
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Age 18 years or more.
- Patients with Uncontrolled bronchial asthma, frequent exacerbations and difficult to treat symptoms despite adherence to medication.
Who cannot join
- Age less than 18 years.
- Patients who do not give consent for the procedure.
- Patients with unstable cardiac conditions (recent myocardial infarction, cardiac arrhythmia, etc.)
- Pregnant women.
- Patient already on antifungal treatment.
- Bleeding profile abnormality.
- patients during acute sever attacks .
About this study
This study is to assess the pattern of isolated fungi from the respiratory air way (bronchial tree) from bronchoalvealar lavage (BAL) in asthmatic patients with uncontrolled or difficult to treat asthma
Read the detailed description
Asthma is a heterogeneous disease, usually characterized by chronic airway inflammation and hyper responsiveness. It is defined by the history of respiratory symptoms, such as wheeze, shortness of breath, chest tightness and cough, that vary over time and in intensity, together with variable expiratory airflow limitation. Airflow limitation may later become persistent Making the diagnosis of asthma is based on identifying both a characteristic pattern of respiratory symptoms such as wheezing, shortness of breath (dyspnea), chest tightness or cough, and variable expiratory airflow limitation (Levy ML et al,2006 ) In asthma, lung function may vary between completely normal and severely obstructed in the same patient. Poorly controlled asthma is associated with greater variability in lung function than well-controlled asthma (Graham BL et al,2019 ) A reduced FEV1 may be found with many other lung diseases (or poor spirometric technique), but a reduced ratio of FEV1 to forced vital capacity (FEV1/FVC), compared with the lower limit of normal, indicates expiratory airflow limitation Most patients with asthma can be well-controlled with low doses of anti- inflammatory agents. However, up to 10% of patients with asthma manifest with severe disease, which leads to considerable limitation of activities of daily life and can be fatal .(Moore et al.,2007).
Severe asthma remains a challenge for patients and clinicians, as these patients are not only difficult to treat but also contribute disproportionately to the overall costs of asthma .
The reasons for the variation in severity of asthma from patient to patient are not fully understood. Several environmental factors, such as house dust mite, animal dander from pets, and environmental fungi (especially their continued exposure), are known to worsen asthma control (GINA ,2023).
Fungal diseases are a concern in the medical and public health community because of the increasing number of people with weakened immune systems and the advances in health care practices.
Fungi can be linked to severe asthma in a multitude of ways, including (inhalation of fungal spores; fungal sensitization,and allergic bronchopulmonary aspergillosis (ABPA) a severe degree of fungal sensitization culminating in irreversible bronchopulmonary damage Fungal infections are difficult to diagnose because clinical symptoms, signs, and radiographic manifestations are unspecific. Therefore, a definitive diagnosis requires direct identification of fungi from the site of infection.
Funal infection of air way can be diagnosed by :
- Microscopic Examination
- Culture of respiratory secretions (sputum,BAL), tissue samples, or blood.
- Serology : assay of serum that detect host antibodies reacting to fungal elements.
- Antigen antibodie :detection of components of the fungal wall that are shed into the bloodstream or other body fluids as the organism proliferates.
- PCR Up to 70% of severe asthmatics are IgE sensitized to fungi compared with 10% of mild-to-moderate asthmatics and 5% of the general population (RICK et al.,2020).
Exposure to outdoor fungal spores has been associated with worsening asthma symptoms, poor lung function, hospital admissions, and asthma- related death.(Agarwal et al.,2011).
Bronchoscopy is used as a diagnostic tool to observe endobronchial lesions and to obtain clinical specimens such as bronchoalveolar lavage (BAL) and bronchial washing. Fungal culture examination from clinical specimen of bronchoscopy could assist in diagnosing pulmonary mycosis (Hermansyah et al.,2021).
Bronchoalveolar lavage (BAL) is a common and relatively safe diagnostic procedure for the evaluation of patients with lung disease. It often provides valuable diagnostic information when clinical history, physical exam, routine laboratory testing, pulmonary function testing and radiographic imaging are insufficient to reach a definitive diagnosis. Compared to sputum analysis, BAL allows for targeted sampling of the lower respiratory tract with less microbial contamination from the upper aerodigestive tract (Davidson et al.,2020).
Aim of Work:
The aim of this study is to assess the pattern of isolated fungi from the respiratory air way (bronchial tree) from bronchoalvealar lavage (BAL) in asthmatic patients with uncontrolled or difficult to treat asthma .
Study Design:
Prospective, cross sectional, observational study . study locality: All adult patients (>18 years) with difficult to treat bronchial asthma or frequent exacerbation , admitted to or follow in outpatient clinic in Mansoura University chest department and Damietta chest hospital .
Sample Size :
(BAL) will collected from 60 patients with bronchial asthma
Patients and Methods:
Patients with Uncontrolled bronchial asthma, frequent exacerbations and difficult to treat symptoms despite adherence to medication according to (GINA 2023).
Patients will classified according to Asthma Control Questionnaire (ACQ GINA2023 Asthma Control Questionnaire (ACQ):
In the past 4 weeks, has the patient had:
- Daytime asthma symptoms more than twice/week? Yes No
- Any night waking due to asthma? Yes No
- SABA* reliever for symptoms more than twice/week? Yes No
- Any activity limitation due to asthma? Yes NO Well controlled: Non of these . Partly controlled: 1-2 Uncontrolled :3-4 Inclusion criteria
- Age 18 years or more.
- Patients with Uncontrolled bronchial asthma, frequent exacerbations and difficult to treat symptoms despite adherence to medication.
Exclusion criteria
- Age less than 18 years.
- Patients who do not give consent for the procedure.
- Patients with unstable cardiac conditions (recent myocardial infarction, cardiac arrhythmia, etc.)
- Pregnant women.
- Patient already on antifungal treatment.
- Bleeding profile abnormality.
- patients during acute sever attacks .
All the patients will be subjected to the following:
- Clinical evaluation:
- Full history taking and clinical examination.
- Laboratory work up:
- CBC
- Bleeding profile (INR)
- ECG
- pulmonary function test (pfts)with reversibility test Positive bronchodilator (BD) responsiveness (reversibility test) Is consider in adults if : increase in FEV1 of >12% and >200 mL (greater confidence if increase is >15% and >400 mL).
Measure change 10-15 minutes after 200-400 mcg salbutamol (albuterol) or equivalent, compared with pre-BD readings.
Before bronchodilator reversibility testing, short-acting and long-acting inhaled bronchodilators were withheld 4 and 12 hours; short-acting and long-acting oral bronchodilators were withheld 8 and 12 hours before testing, respectively Radiological work up
- CT chest or chest x ray 6- Bronchoscopy with BAL: Bronchoscopy with BAL was performed according to standardized procedures designed to minimize oral contamination. BAL was performed by sequentially instilling and then withdrawing 50 ml aliquots of sterile normal saline.
Bronchoalveolar lavage fluid specimens collected under aseptic precautions was immediately transported to the laboratory for fungal processing BAL fluid should be collected in a labeled sterile container and transported expediently to the laboratory for analysis.
Microbiology work up :
BAL will stained by fungal staining with lactophenol stain as well as culture on Sabouraud dextrose agar.
Some pathogenic fungi grow slowly in culture and require plates to be held for up to 2 weeks, and in some case up to 4 weeks, before being discarded as negative. However, many common pathogenic fungi, such as Aspergillus fumigatus and Candida albicans, will produce identifiable colonies within 1-3days. Cultures should be examined at frequent intervals (at least three times weekly) .
Statistical analysis:
The collected data will be coded, processed and analyzed using SPSS program (Version 26) for windows. The appropriate statistical tests will be used when needed. P values less than 0.05 (5%) will be considered to be statically significant.
Ethical consideration:
- Study protocol will be submitted for approval by IRB
- Approval of the mangers of the health care facilities in which the study will be conducted
- Informed written consent will be obtained from each participant sharing in the study.
- Confidentiality and personal privacy will be respected in all levels of the study. Collected data will not be used for any other purpose
- Conditions
- Bronchial Asthma
- Being tested
- fibroptic bronchoscopy
- Medical subject headings
- Asthma
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
fibroptic bronchoscopyDevice
Also called fugnal stain and culcure
take bal through fibrooptic bronchoscopy and send for stain and culcure
| Study group | Role | What they receive |
|---|---|---|
| Study patern of fungal inection which cause excerbation | Other | Take bal through fob and send for fungal stain and culure Receives: Device: fibroptic bronchoscopy |
What is being measured
The primary outcome is the main question the study is designed to answer.
assess the pattern of isolated fungi from the respiratory air way (bronchial tree) from bronchoalvealar lavage (BAL) in asthmatic patients with uncontrolled or difficult to treat asthma
BAL will stained by fungal staining with lactophenol stain as well as culture on Sabouraud dextrose agar.
Measured: 1 year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted19 Apr 2024
- Study start25 Apr 2024 (estimated)
- Primary completion20 Apr 2025 (estimated)
- Study completion20 May 2025 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Bronchial AsthmaStudies of the same condition, open and under way.
- More trials run by Mansoura UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Diagnosis
- Allocation
- Not applicable
- Intervention model
- Single group
- Model description
- BAL will stained by fungal staining with lactophenol stain as well as culture on Sabouraud dextrose agar.
- Masking
- None (open label)
- Enrolment
- 60 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Mansoura University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Tamer Awad, Mansoura University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06376617
- Sponsor's protocol ID
- MS.24.03.2743
- Status last verified
- Apr 2024
- First submitted
- 16 Apr 2024
- Last updated
- 19 Apr 2024
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 19 Apr 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Pattern Of Isolated Fungi From Bronchoalveolar Lavage Among Patients With Bronchial Asthma
- ClinicalTrials.gov ID
- NCT06376617
- Acronym / sponsor ID
- MS.24.03.2743
- Conditions
- Bronchial Asthma
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 60 participants (estimated)
- Lead sponsor
- Mansoura UniversityUniversity, hospital or other
- Study start
- 25 Apr 2024 (estimated)
- Primary completion
- 20 Apr 2025 (estimated)
- Study completion
- 20 May 2025 (estimated)
- First posted
- 19 Apr 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study is to assess the pattern of isolated fungi from the respiratory air way (bronchial tree) from bronchoalvealar lavage (BAL) in asthmatic patients with uncontrolled or difficult to treat asthma
Detailed description
Asthma is a heterogeneous disease, usually characterized by chronic airway inflammation and hyper responsiveness. It is defined by the history of respiratory symptoms, such as wheeze, shortness of breath, chest tightness and cough, that vary over time and in intensity, together with variable expiratory airflow limitation. Airflow limitation may later become persistent Making the diagnosis of asthma is based on identifying both a characteristic pattern of respiratory symptoms such as wheezing, shortness of breath (dyspnea), chest tightness or cough, and variable expiratory airflow limitation (Levy ML et al,2006 ) In asthma, lung function may vary between completely normal and severely obstructed in the same patient. Poorly controlled asthma is associated with greater variability in lung function than well-controlled asthma (Graham BL et al,2019 ) A reduced FEV1 may be found with many other lung diseases (or poor spirometric technique), but a reduced ratio of FEV1 to forced vital capacity (FEV1/FVC), compared with the lower limit of normal, indicates expiratory airflow limitation Most patients with asthma can be well-controlled with low doses of anti- inflammatory agents. However, up to 10% of patients with asthma manifest with severe disease, which leads to considerable limitation of activities of daily life and can be fatal .(Moore et al.,2007).
Severe asthma remains a challenge for patients and clinicians, as these patients are not only difficult to treat but also contribute disproportionately to the overall costs of asthma .
The reasons for the variation in severity of asthma from patient to patient are not fully understood. Several environmental factors, such as house dust mite, animal dander from pets, and environmental fungi (especially their continued exposure), are known to worsen asthma control (GINA ,2023).
Fungal diseases are a concern in the medical and public health community because of the increasing number of people with weakened immune systems and the advances in health care practices.
Fungi can be linked to severe asthma in a multitude of ways, including (inhalation of fungal spores; fungal sensitization,and allergic bronchopulmonary aspergillosis (ABPA) a severe degree of fungal sensitization culminating in irreversible bronchopulmonary damage Fungal infections are difficult to diagnose because clinical symptoms, signs, and radiographic manifestations are unspecific. Therefore, a definitive diagnosis requires direct identification of fungi from the site of infection.
Funal infection of air way can be diagnosed by :
- Microscopic Examination
- Culture of respiratory secretions (sputum,BAL), tissue samples, or blood.
- Serology : assay of serum that detect host antibodies reacting to fungal elements.
- Antigen antibodie :detection of components of the fungal wall that are shed into the bloodstream or other body fluids as the organism proliferates.
- PCR Up to 70% of severe asthmatics are IgE sensitized to fungi compared with 10% of mild-to-moderate asthmatics and 5% of the general population (RICK et al.,2020).
Exposure to outdoor fungal spores has been associated with worsening asthma symptoms, poor lung function, hospital admissions, and asthma- related death.(Agarwal et al.,2011).
Bronchoscopy is used as a diagnostic tool to observe endobronchial lesions and to obtain clinical specimens such as bronchoalveolar lavage (BAL) and bronchial washing. Fungal culture examination from clinical specimen of bronchoscopy could assist in diagnosing pulmonary mycosis (Hermansyah et al.,2021).
Bronchoalveolar lavage (BAL) is a common and relatively safe diagnostic procedure for the evaluation of patients with lung disease. It often provides valuable diagnostic information when clinical history, physical exam, routine laboratory testing, pulmonary function testing and radiographic imaging are insufficient to reach a definitive diagnosis. Compared to sputum analysis, BAL allows for targeted sampling of the lower respiratory tract with less microbial contamination from the upper aerodigestive tract (Davidson et al.,2020).
Aim of Work:
The aim of this study is to assess the pattern of isolated fungi from the respiratory air way (bronchial tree) from bronchoalvealar lavage (BAL) in asthmatic patients with uncontrolled or difficult to treat asthma .
Study Design:
Prospective, cross sectional, observational study . study locality: All adult patients (>18 years) with difficult to treat bronchial asthma or frequent exacerbation , admitted to or follow in outpatient clinic in Mansoura University chest department and Damietta chest hospital .
Sample Size :
(BAL) will collected from 60 patients with bronchial asthma
Patients and Methods:
Patients with Uncontrolled bronchial asthma, frequent exacerbations and difficult to treat symptoms despite adherence to medication according to (GINA 2023).
Patients will classified according to Asthma Control Questionnaire (ACQ GINA2023 Asthma Control Questionnaire (ACQ):
In the past 4 weeks, has the patient had:
- Daytime asthma symptoms more than twice/week? Yes No
- Any night waking due to asthma? Yes No
- SABA* reliever for symptoms more than twice/week? Yes No
- Any activity limitation due to asthma? Yes NO Well controlled: Non of these . Partly controlled: 1-2 Uncontrolled :3-4 Inclusion criteria
- Age 18 years or more.
- Patients with Uncontrolled bronchial asthma, frequent exacerbations and difficult to treat symptoms despite adherence to medication.
Exclusion criteria
- Age less than 18 years.
- Patients who do not give consent for the procedure.
- Patients with unstable cardiac conditions (recent myocardial infarction, cardiac arrhythmia, etc.)
- Pregnant women.
- Patient already on antifungal treatment.
- Bleeding profile abnormality.
- patients during acute sever attacks .
All the patients will be subjected to the following:
- Clinical evaluation:
- Full history taking and clinical examination.
- Laboratory work up:
- CBC
- Bleeding profile (INR)
- ECG
- pulmonary function test (pfts)with reversibility test Positive bronchodilator (BD) responsiveness (reversibility test) Is consider in adults if : increase in FEV1 of >12% and >200 mL (greater confidence if increase is >15% and >400 mL).
Measure change 10-15 minutes after 200-400 mcg salbutamol (albuterol) or equivalent, compared with pre-BD readings.
Before bronchodilator reversibility testing, short-acting and long-acting inhaled bronchodilators were withheld 4 and 12 hours; short-acting and long-acting oral bronchodilators were withheld 8 and 12 hours before testing, respectively Radiological work up
- CT chest or chest x ray 6- Bronchoscopy with BAL: Bronchoscopy with BAL was performed according to standardized procedures designed to minimize oral contamination. BAL was performed by sequentially instilling and then withdrawing 50 ml aliquots of sterile normal saline.
Bronchoalveolar lavage fluid specimens collected under aseptic precautions was immediately transported to the laboratory for fungal processing BAL fluid should be collected in a labeled sterile container and transported expediently to the laboratory for analysis.
Microbiology work up :
BAL will stained by fungal staining with lactophenol stain as well as culture on Sabouraud dextrose agar.
Some pathogenic fungi grow slowly in culture and require plates to be held for up to 2 weeks, and in some case up to 4 weeks, before being discarded as negative. However, many common pathogenic fungi, such as Aspergillus fumigatus and Candida albicans, will produce identifiable colonies within 1-3days. Cultures should be examined at frequent intervals (at least three times weekly) .
Statistical analysis:
The collected data will be coded, processed and analyzed using SPSS program (Version 26) for windows. The appropriate statistical tests will be used when needed. P values less than 0.05 (5%) will be considered to be statically significant.
Ethical consideration:
- Study protocol will be submitted for approval by IRB
- Approval of the mangers of the health care facilities in which the study will be conducted
- Informed written consent will be obtained from each participant sharing in the study.
- Confidentiality and personal privacy will be respected in all levels of the study. Collected data will not be used for any other purpose
Study design
- Primary purpose
- Diagnosis
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
- Model description
- BAL will stained by fungal staining with lactophenol stain as well as culture on Sabouraud dextrose agar.
| Arm | Type | Receives |
|---|---|---|
| Study patern of fungal inection which cause excerbation | Other | Device: fibroptic bronchoscopyTake bal through fob and send for fungal stain and culure |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (2 listed)
- Age 18 years or more.
- Patients with Uncontrolled bronchial asthma, frequent exacerbations and difficult to treat symptoms despite adherence to medication.
Key exclusion criteria (7 listed)
- Age less than 18 years.
- Patients who do not give consent for the procedure.
- Patients with unstable cardiac conditions (recent myocardial infarction, cardiac arrhythmia, etc.)
- Pregnant women.
- Patient already on antifungal treatment.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| fibroptic bronchoscopyAlso: fugnal stain and culcuretake bal through fibrooptic bronchoscopy and send for stain and culcure | Device | Study patern of fungal inection which cause excerbation |
Primary outcome
assess the pattern of isolated fungi from the respiratory air way (bronchial tree) from bronchoalvealar lavage (BAL) in asthmatic patients with uncontrolled or difficult to treat asthma
Time frame: 1 year
BAL will stained by fungal staining with lactophenol stain as well as culture on Sabouraud dextrose agar.
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 19 Apr 2024.
Related trials for Bronchial Asthma
RecruitingPhase 1
Pilot Study to Identify the Mediators and Inflammatory Cell Surface Receptors Involved in Allergic Airway Inflammation
Asthma
RecruitingPhase 1
A Study to Compare the Relative Potency of Salbutamol Administered Via Metered Dose Inhalers (MDI) Containing Propellants HFA-152a to HFA-134a in Mild Asthmatics Aged 18 to 65 Inclusive
Asthma, Mild Asthma
RecruitingPhase 3
A Study Assessing the Effect of Dupilumab on Inducing Clinical Remission in Asthma
Asthma Control
Active, not recruitingPhase 2/3
Local Antibiotic Delivery for Community Acquired Pneumonia
Community Acquired Pneumonia (CAP)
RecruitingPhase 2
A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate-To-Severe Asthma
Asthma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
Questions about this trial
What is this clinical trial studying?
A study testing fibroptic bronchoscopy in people with Bronchial Asthma, run by Mansoura University.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 19 Apr 2024. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
assess the pattern of isolated fungi from the respiratory air way (bronchial tree) from bronchoalvealar lavage (BAL) in asthmatic patients with uncontrolled or difficult to treat asthma (time frame: 1 year). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 Apr 2024.